BioXcel unveils data from Phase 1 study of receptor agonist BXCL501
Category: #health  By Mateen Dalal  Date: 2019-05-21
  • share
  • Twitter
  • Facebook
  • LinkedIn

BioXcel unveils data from Phase 1 study of receptor agonist BXCL501

Sublingual administration of BXCL501 had achieved drug exposures that will be therapeutic for the acute treatment of agitation

Reports confirm that BioXcel Therapeutics (BTI) has recently presented data from its Phase 1 pharmacokinetic (bioavailability) and safety study of the company’s product candidate BXCL501. It is a proprietary sublingual thin-film preparation of dexmedetomidine aimed at acute treatment of agitation across several neuropsychiatric indications.

Sources close to the matter informed that administration of BXCL501 in the Phase 1 safety and pharmacokinetic (PK) study successfully achieved targeted exposure levels that were experienced to be therapeutic in previous IV Dex study of the company and for evaluation of efficacy in agitated schizophrenia patients, BTI intends to advance BXCL501 into a Phase 2 study.

The company hopes that the results from the Phase 2 trial would help power a planned Phase 3 pivotal trial.

Apparently, BTI is a clinical-stage biopharmaceutical development company applying new artificial intelligence approaches to recognize and advance next wave of medicines in immuno-oncology and neuroscience.

The IND-opening Phase 1 study was seemingly a double-blinded placebo-controlled, dose-escalation, single-dose study of BXCL501 that had 42 adult volunteers enrolled for several dosing groups. The primary endpoints of the study were safety and PK, while secondary endpoints contained assessment of pharmacodynamics and the relationship between PD endpoints and BXCL501 concentrations.

Sources mentioned that in November 2018, the company had unveiled findings from the study which showed that BXCL501 swiftly achieved targeted exposure levels compatible with the levels observed in the intravenous Dex study in schizophrenia patients. Results from the Phase 1 study also indicated dose-proportional PK consistent with the IV Dex trial along with PD effects lasting 4 to 6 hours, which company believes are clinically favourable features.

According to Chief Executive Officer of BioXcel Therapeutics, (Ph.D.) Vimal Mehta, in Phase 1 study the sublingual administration of BXCL501 had achieved drug exposures that will be therapeutic in the acute treatment of agitation. Besides, the PK profile of sublingual BXCL501 defined proportionality of dose and the potential for a fast onset of action.

Source Credit: http://www.globenewswire.com/news-release/2019/05/20/1827676/0/en/BioXcel-Therapeutics-Achieved-Targeted-Exposures-of-BXCL501-Designed-For-Non-Invasive-Acute-Treatment-of-Agitation-in-Neuropsychiatric-Diseases.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Applied Therapeutics unveils Phase 1/2 trial of Galactosemia treatment
Applied Therapeutics unveils Phase 1/2 trial of Galactosemia treatment
By Mateen Dalal

Galactosemia patients are in urgent need of treatment options and the company is committed to advancing AT-007 through clinical development Reports confirm that Applied Therapeutics Inc. has recently unveiled the initiation of a Phase 1/2 clinical t...

Security concerns drive Microsoft to ban internal use of Slack, AWS
Security concerns drive Microsoft to ban internal use of Slack, AWS
By Mateen Dalal

Microsoft believes various versions of Slack do not offer sufficient controls to protect its intellectual property Microsoft has reportedly barred its more than 100,000 employees from using the free version of Slack. Apparently, Microsoft has come u...

Harley-Davidson inks deal to make smaller motorcycles in China
Harley-Davidson inks deal to make smaller motorcycles in China
By Mateen Dalal

The new bikes would have a 338cc engine, by far the smallest engine model Harley has ever made, and will be sold in China by late 2020. American motorcycle manufacturer Harley-Davidson has reportedly announced to have inked a partnership with C...